PYC’s third quarter update highlights progress made in its...

PYC’s third quarter update highlights progress made in its transition to becoming a clinicalstage company. The anticipated timing for completion of this milestone is the second half of 2022.
These milestones achieved in Q3 are important for two reasons, they:

i) support the build-up of information in the Company’s plan to submit an Investigational New Drug (IND) application to the United States Food and Drug Administration in the RP11 program within the next 12 months; and

ii) validate and de-risk PYC’s platform and deep ocular pipeline due to the similarities between the drug candidate evaluated in these studies and the rest of PYC’s pipeline for blinding eye diseases caused by different genetic mutations.

Successful safety and tolerability assessments in the RP11 program (the data to be released in the near future) will see PYC:
- Progress to within reach of a first in human study;
- With a validated and highly scalable platform technology that supports multiple drug programs;
- Where the cornerstone of PYC’s pipeline (its first in class and best in class diseasemodifying therapies for monogenic diseases) have an extraordinarily high prospect of successful approval2

The science does sound upbeat with every ann, the trading does the opposite.
Place yourself on the right side of the equation to profit as trading will follow suit
when those who wish to position themselves have done so.

all IMO